Ірландія - англійська - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - carmustine - powder and solvent for concentrate for solution for infusion - carmustine

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - carmustine - powder and solvent for concentrate for solution for infusion - carmustine

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - carmustine, quantity: 100 mg - injection, diluent for - excipient ingredients: ethanol absolute - carmustine-drla is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: 1. malignant glioma 2. multiple myeloma - in combination with prednisone. 3. hodgkin?s disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. 4. non-hodgkin?s lymphomas - as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy or who fail to respond to primary therapy.

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

tillomed pharma gmbh - carmustine - powder and solvent for concentrate for solution for infusion - 100 milligram(s) - nitrosoureas; carmustine

Ізраїль - англійська - Ministry of Health

k.s.kim international ltd - carmustine - powder and solvent for concentrate for solution for infusion - carmustine 100 mg - carmustine - carmustine is indicated as palliative therapy as a single agent or in established combination therapy with other approved agents in the following:• brain tumors - glioblastoma, medulloblastoma, astrocytoma and metastatic brain tumors.• multiple myeloma - in combination with glucocorticoid such as prednisone. • hodgkin’s disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.• non-hodgkin’s lymphomas - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.

США - англійська - NLM (National Library of Medicine)

arbor pharmaceuticals - carmustine (unii: u68wg3173y) (carmustine - unii:u68wg3173y) - carmustine 7.7 mg - gliadel wafer is indicated for the treatment of patients with: - newly-diagnosed high-grade glioma as an adjunct to surgery and radiation, and - recurrent glioblastoma as an adjunct to surgery. none. risk summary gliadel wafer can cause fetal harm when administered to a pregnant woman. there are no available data on gliadel use in pregnant women. there have been no animal reproductive studies with gliadel wafer; however, carmustine, the active component of gliadel wafer, is embryotoxic and teratogenic in rats at exposures less than the exposure at the recommended human dose based on body surface area (bsa) and embryotoxic in rabbits at exposures similar to exposures at the recommended human dose based on bsa (see data) . advise pregnant women of the potential risk to a fetus. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data animal data there are no studies assessing the repro

США - англійська - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - carmustine (unii: u68wg3173y) (carmustine - unii:u68wg3173y) - carmustine 100 mg in 30 ml - bicnu® (carmustine for injection) is indicated as palliative therapy as a single agent or in established combination therapy in the following: - brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - multiple myeloma in combination with prednisone. - relapsed or refractory hodgkin's lymphoma in combination with other approved drugs. - relapsed or refractory non-hodgkin's lymphomas in combination with other approved drugs. bicnu is contraindicated in patients with previous hypersensitivity to bicnu or its components. risk summary bicnu (carmustine for injection) can cause fetal harm when administered to a pregnant woman based on the mechanism of action [see clinical pharmacology (12.1) ] and findings in animals [see data] . limited available data with bicnu use in pregnant women are insufficient to inform a drug-associated risk of major birth defects and miscarriage. carmustine was embryotoxic in rats and rabbits and teratogenic in rats (thoracoabd

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - carmustine, quantity: 100 mg - diluent, not applicable - excipient ingredients: ethanol absolute - carmustine intas is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following:,1. malignant glioma,2. multiple myeloma - in combination with prednisone.,3. hodgkin?s disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.,4. non-hodgkin?s lymphomas - as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy or who fail to respond to primary therapy.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - carmustine, quantity: 100 mg - injection, diluent for - excipient ingredients: ethanol absolute - carmustine dr.reddy's is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: 1. malignant glioma 2. multiple myeloma - in combination with prednisone. 3. hodgkin?s disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. 4. non-hodgkin?s lymphomas - as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy or who fail to respond to primary therapy.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - carmustine, quantity: 100 mg - injection, powder for - excipient ingredients: - carmustine sxp is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following:,1. malignant glioma,2. multiple myeloma - in combination with prednisone.,3. hodgkin?s disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.,4. non-hodgkin?s lymphomas - as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy or who fail to respond to primary therapy.